Peter John Smith

7.2k citations

145 papers · 6.0k · 1 hit paper · h-index 41

Impact in

Infectious Diseases top 1%
- Tuberculosis Research and Epidemiology
- HIV/AIDS drug development and treatment
Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
- Antibiotics Pharmacokinetics and Efficacy

Papers in

Infectious Diseases 50
- HIV/AIDS drug development and treatment 37
- Tuberculosis Research and Epidemiology 15
Physical and Theoretical Chemistry 25
- Photochemistry and Electron Transfer Studies 23

Co-authors: Helen McIlleron (40 shared papers)Gary Maartens (20 shared papers)Allen H. Heller (1 shared paper)Patrick D. Lilly (1 shared paper)Karluss Thomas (1 shared paper)A. M. Monro (1 shared paper)Gerald J. Kolaja (1 shared paper)William M. Bracken (1 shared paper)
Journals: Antimicrobial Agents and Chemotherapy (17 papers)Canadian Journal of Chemistry (10 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (6 papers)The Journal of Physical Chemistry (5 papers)European Journal of Clinical Pharmacology (4 papers)
Partner nations: South Africa United States United Kingdom

In The Last Decade

Peter John Smith

145 papers receiving 5.7k citations

Peter John Smith's Hit Papers

align trajectories log scale

Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals 2000 · 1.6k citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2000 Regulatory Toxicology and Pharmacology

Peers

Countries citing papers authored by Peter John Smith

Since Specialization

Citations

This map shows the geographic impact of Peter John Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter John Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter John Smith more than expected).

Fields of papers citing papers by Peter John Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter John Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter John Smith. The network helps show where Peter John Smith may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter John Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter John Smith Line = papers co-authored together Peter John Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 145 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals Regulatory Toxicology and Pharmacology ·Harry M. Olson, Graham R. Betton, Denise E. Robinson, Karluss Thomas, A. M. Monro, Gerald J. Kolaja, Patrick D. Lilly, James Sanders Hit paper breakdown →	2000	1631
2	Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears Antimicrobial Agents and Chemotherapy ·Andreas Henri Diacon, Ramonde F. Patientia, Amour Venter, Paul D. van Helden, Peter John Smith, Helen McIlleron, J. S. Maritz, Peter Roderick Donald	2007	177
3	Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption Antimicrobial Agents and Chemotherapy ·Justin J. Wilkins, Radojka M. Savić, Mats O. Karlsson, Grant Langdon, Helen McIlleron, Goonaseelan Colin Pillai, Peter John Smith, Ulrika S. H. Simonsson	2008	133
4	The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications Antimicrobial Agents and Chemotherapy ·Emmanuel Chigutsa, Marianne E Visser, Rina Swart, Paolo Denti, Sudeep P. Pushpakom, Deirdre Egan, Nicholas H. G. Holford, Peter John Smith	2011	126
5	Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery Drug Discovery Today ·Moses M. Hohman, Kellan Gregory, Kelly Chibale, Peter John Smith, Sean Ekins, Barry A. Bunin	2009	120
6	Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis Antimicrobial Agents and Chemotherapy ·Emmanuel Chigutsa, Jotam G. Pasipanodya, Marianne E. Visser, Paul D. van Helden, Peter John Smith, Frederick Adriaan Sirgel, Tawanda Gumbo, Helen McIlleron	2014	118
7	Isoniazid Plasma Concentrations in a Cohort of South African Children with Tuberculosis: Implications for International Pediatric Dosing Guidelines Clinical Infectious Diseases ·Helen McIlleron, Marianne Willemse, Cedric J. Werely, Gregory Dudley Hussey, Hendrik Simon Schaaf, Peter John Smith, Peter Roderick Donald	2009	105
8	Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting JAIDS Journal of Acquired Immune Deficiency Syndromes ·Gert Uves van Zyl, Thijs E. van Mens, Helen McIlleron, M. Zeier, Jean Bisimwa Nachega, Eric H. Decloedt, Carolina Malavazzi, Peter John Smith	2011	97
9	Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients British Journal of Clinical Pharmacology ·Justin J. Wilkins, Grant Langdon, Helen McIlleron, Goonaseelan Colin Pillai, Peter John Smith, Ulrika S. H. Simonsson	2011	90
10	Effect of Rifampicin on Lopinavir Pharmacokinetics in HIV-Infected Children With Tuberculosis JAIDS Journal of Acquired Immune Deficiency Syndromes ·Yuan Ren, James J. C. Nuttall, Claire Egbers, Brian Stephen Eley, Tammy Meyers, Peter John Smith, Gary Maartens, Helen McIlleron	2008	89
11	Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines Antimicrobial Agents and Chemotherapy ·Helen McIlleron, Roxana Rustomjee, Mahnaz Vahedi, Thuli Mthiyane, Paolo Denti, Catherine Anne Connolly, WASIMA N. RIDA, Alexander S. Pym	2012	86
12	A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients Antimicrobial Agents and Chemotherapy ·Wynand A. Smythe, Akash Khandelwal, Corinne Simone Merle, Roxana Rustomjee, Martin Gninafon, Mame Bocar Lo, Oumou Bah Sow, Piero Olliaro	2012	82
13	Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers European Journal of Clinical Pharmacology ·Catherine Orrell, Francesca Little, Peter John Smith, Peter Ian Folb, Walter R. J. Taylor, Piero Olliaro, Karen Irma Barnes	2008	75
14	Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. PubMed ·Karen Cohen, Alison D. Grant, Collet Dandara, Helen McIlleron, Lindiwe Pemba, Katherine Fielding, Salome Charalombous, Gavin Churchyard	2009	72
15	Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction Antimicrobial Agents and Chemotherapy ·Maxwell Chirehwa, Roxana Rustomjee, Thuli Mthiyane, Philip Onyebujoh, Peter John Smith, Helen McIlleron, Paolo Denti	2015	70
16	Pharmacogenetics of plasma efavirenz exposure in HIV‐infected adults and children in South Africa British Journal of Clinical Pharmacology ·Phumla Sinxadi, Paul Denis Leger, Helen McIlleron, Peter John Smith, Joel Alex Dave, Naomi Sharlene Levitt, Gary Maartens, David W. Haas	2015	70
17	Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients European Journal of Clinical Pharmacology ·Justin J. Wilkins, Grant Langdon, Helen McIlleron, Goonaseelan Colin Pillai, Peter John Smith, Ulrika S. H. Simonsson	2006	69
18	Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa Antiviral Therapy ·Karen Cohen, Alison D. Grant, Collet Dandara, Helen McIlleron, Lindiwe Pemba, Katherine Fielding, Salome Charalombous, Gavin Churchyard	2008	68
19	Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis BMC Medicine ·Hendrik Simon Schaaf, Marianne Willemse, Karien Cilliers, Demetre Labadarios, J.S. Maritz, Gregory Dudley Hussey, Helen McIlleron, Peter John Smith	2009	68
20	High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients Pharmacogenetics and Genomics ·Marelize Swart, Michelle Skelton, Yuan Ren, Peter John Smith, Simbarashe G. Takuva, Collet Dandara	2013	66

About Peter John Smith

Peter John Smith is a scholar working on Infectious Diseases, Physical and Theoretical Chemistry, Biophysics, Organic Chemistry and Pharmacology, having authored 145 papers that have together received 6.0k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (37 papers), Photochemistry and Electron Transfer Studies (23 papers), Free Radicals and Antioxidants (22 papers), Electron Spin Resonance Studies (19 papers), Radical Photochemical Reactions (16 papers), Malaria Research and Control (16 papers), Tuberculosis Research and Epidemiology (15 papers) and Antibiotics Pharmacokinetics and Efficacy (12 papers). The work is most often cited by research in Infectious Diseases (1.9k citations), Pharmacology (844 citations), Virology (280 citations), Small Animals (288 citations) and Pharmacology (469 citations). Peter John Smith has collaborated with scholars based in South Africa, United States and United Kingdom. Frequent co-authors include Helen McIlleron, Gary Maartens, Allen H. Heller, Patrick D. Lilly, Karluss Thomas, A. M. Monro, Gerald J. Kolaja, William M. Bracken, Bruce M. Berger and Harry M. Olson. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Canadian Journal of Chemistry, JAIDS Journal of Acquired Immune Deficiency Syndromes, The Journal of Physical Chemistry and European Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Peter John Smith

Impact in

Papers in i

In The Last Decade

Peter John Smith

Peter John Smith's Hit Papers

Peers

Countries citing papers authored by Peter John Smith

Fields of papers citing papers by Peter John Smith

All Works

About Peter John Smith

Explore authors with similar magnitude of impact

Papers in